Stock Market News
Victrex now fully valued, thinks Berenberg
(WebFG News) - Polymers manufacturer Victrex has had a good run, but as far as analysts at Berenberg were concerned, it was time to downgrade the firm to 'hold' as it was now fully valued.
After seeing shares rally roughly 20% since September, outperforming the European chemicals sector by over 15%, Berenberg dropped Victrex from its 'buy' rating as its stock had reached the price target of 2,700p.
"Investors have clearly warmed to a combination of volume-driven 2018 earnings upgrades and progress towards implementing the company's downstream pipeline," Berenberg's Tuesday morning research note read.
"But the absence of further upgrades and [the] prospect of FX-headwinds leaving earnings flat-down in 2019 leave little scope for a further re-rating, in our view."
Berenberg noted that Victrex's dividend yield of 4.6% was still "attractive" compared to the Stoxx 600 Chemicals average of 2.9%, but saw "limited upside" without any earnings upgrades from the drugmaker.
The analysts left their price target on Victrex unchanged, noting that while there was clearly scope for the company to re-rate further in the long term, especially if it delivers on its pipeline ambitions, FX and tougher comparable numbers are likely to limit the group's near-term upside.
After seeing shares rally roughly 20% since September, outperforming the European chemicals sector by over 15%, Berenberg dropped Victrex from its 'buy' rating as its stock had reached the price target of 2,700p.
"Investors have clearly warmed to a combination of volume-driven 2018 earnings upgrades and progress towards implementing the company's downstream pipeline," Berenberg's Tuesday morning research note read.
"But the absence of further upgrades and [the] prospect of FX-headwinds leaving earnings flat-down in 2019 leave little scope for a further re-rating, in our view."
Berenberg noted that Victrex's dividend yield of 4.6% was still "attractive" compared to the Stoxx 600 Chemicals average of 2.9%, but saw "limited upside" without any earnings upgrades from the drugmaker.
The analysts left their price target on Victrex unchanged, noting that while there was clearly scope for the company to re-rate further in the long term, especially if it delivers on its pipeline ambitions, FX and tougher comparable numbers are likely to limit the group's near-term upside.
Related share prices |
---|
Victrex plc (VCT) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price